Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler® and Diskus® powder devices in healthy volunteers

被引:37
作者
Mackie, AE
McDowall, JE
Falcoz, C
Ventresca, P
Bye, A
Daley-Yates, PT
机构
[1] Glaxo Wellcome Res & Dev, Clin Pharmacol, Greenford UB6 0HE, Middx, England
[2] Eli Lilly & Co, Lilly Res Ctr Ltd, Windlesham GU20 6PH, Surrey, England
关键词
D O I
10.2165/00003088-200039001-00004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: The aim of these studies was to determine the absolute bioavailability in healthy volunteers of inhaled fluticasone propionate (FP) administered as a single dose via the Diskhaler(R) and Diskus(R) powder devices, and the pharmacokinetics of inhaled FP after repeated administration via the Diskhaler(R) device. Methods: In 2 of the studies, single inhaled doses of FP were administered via the Diskhaler(R) and the Diskus(R) powder devices, and, in the third study, repeated doses of FP were administered via the Diskhaler(R). In the single dose studies, 12 healthy volunteers were randomised to receive FP 1000 mug by inhalation and FP 250 mug intravenously, using a double-blind crossover design. In the repeated dose study, 24 healthy volunteers received FP 1000 mug twice daily for 7.5 days. Results: Systemic exposure to FP after administration of a single 1000 mug inhaled dose of FP via the 2 powder devices was similar; the area under the plasma FP concentration-time curve (AUC) to infinite time (AUC,) was 2.08 mug/L . h [95% confidence intervals (CI): 1.63-2.64] for Diskhaler(R) and 2.49 mug/L . h (95% CI: 2.09-2.96) for Diskus(R). Maximum plasma FP concentration (C-max was 0.34 mug/L for both devices. Mean bioavailability values via the Diskhaler(R) and Diskus(R) were 11.9% (95% CI: 9.0-15.7%) and 16.6% (95% CI: 13.6-20.3%), respectively. No clinically significant reductions in urinary cortisol excretion were recorded in these 2 studies. After repeated administration with the Diskhaler(R), steady state was achieved by dose 3 (i.e. day 2) onwards. After dose 15, the AUC up to 12 hours (AUC(12h)) was 2.25 mug/L . h and Cmax was 0.38 mug/L. The mean steady-state to single dose accumulation ratio after twice-daily administration was 1.49 (95% CI: 1.36-1.62). Conclusion: The pharmacokinetics of FP administered by the 2 powder devices are similar in healthy volunteers, although systemic bioavailability was greater with the Diskus(R).
引用
收藏
页码:23 / 30
页数:8
相关论文
共 7 条
[1]   COMPARISON OF DISKUS(TM) INHALER, A NEW MULTIDOSE POWDER INHALER, WITH DISKHALER(TM) INHALER FOR THE DELIVERY OF SALMETEROL TO ASTHMATIC-PATIENTS [J].
BOULET, LP ;
COWIE, R ;
JOHNSTON, P ;
KRAKOVSKY, D ;
MARK, S .
JOURNAL OF ASTHMA, 1995, 32 (06) :429-436
[2]  
Cater J. I., 1995, European Respiratory Journal, V8, p427S
[3]   Comparison of the systemic availability of fluticasone propionate in healthy volunteers and patients with asthma [J].
Daley-Yates, PT ;
Tournant, J ;
Kunka, RL .
CLINICAL PHARMACOKINETICS, 2000, 39 (Suppl 1) :39-45
[4]  
FALCOZ C, 1996, BR J CLIN PHARM, V41, P459
[5]  
Jones B., 1989, DESIGN ANAL CROSS OV
[6]   Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma [J].
Peden, DB ;
Berger, WE ;
Noonan, MJ ;
Thomas, MR ;
Hendricks, VL ;
Hamedani, AG ;
Mahajan, P ;
House, KW .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 102 (01) :32-38
[7]  
Rowland M., 2011, Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications, V4th ed.